GoPath Diagnostics

06/16/2026

GoPath Diagnostics is proud to announce our new national agreement with Capstone Health Alliance, bringing advanced pathology and molecular diagnostic services to hundreds of hospitals across the country. This agreement gives Capstone members direct access to GoPath's full diagnostic portfolio, including molecular oncology, hereditary genetic testing, hematopathology, and digital pathology solutions. For hospital networks looking for a smarter, faster, and more comprehensive lab partner, this is a significant step forward. Better diagnostics, broader access, and stronger patient outcomes at scale.

Read the full announcement: https://www.einpresswire.com/article/918976688/gopath-diagnostics-announces-strategic-national-agreement-with-capstone-health-alliance

06/05/2026

The 86th American Diabetes Association Scientific Sessions start today!

Swing by booth 2220 to learn how DIABETESNOW tests for MODY, syndromic, neonatal, and mitochondrial causes of monogenic diabetes, along with pan-ancestry Type 1 and Type 2 PRS and GenProb-T1D.

06/04/2026

June is National Cancer Survivor Month, a time to honor the strength of over 18.6 million people in the U.S. living with a history of cancer. While survival rates continue to improve thanks to ongoing research, 1 in 4 survivors still reports a poor physical quality of life, reminding us that the work is far from over. This month, we recognize not just the milestones, but the daily realities survivors navigate long after treatment ends. Cancer survivorship is shaped by science, and the more we invest in research, the better outcomes we can create for patients and families everywhere. Take time this June to learn, advocate, and uplift those in your life touched by cancer.

Learn more from the American Association for Cancer Research (AACR) and get involved: https://www.aacr.org/patients-caregivers/awareness-months/national-cancer-survivor-month/

05/28/2026

As Bladder Cancer Awareness Month comes to a close, we want to take a moment to recognize the researchers, patients, and advocates working to change the future of this disease. This May, we are proud to join AACR in shining a light on bladder cancer and the ongoing progress being made. The work is not done, but every step forward matters.

Learn more from the American Association for Cancer Research (AACR):

More than 80,000 people living in the U.S. will be diagnosed with bladder cancer. Learn more about bladder cancer.

05/25/2026

Wishing everyone a meaningful Memorial Day from the GoPath team. 🇺🇸 Today, we take a moment to honor the brave men and women who gave their lives for this country and the freedoms we hold dear. Our hearts go out to every family who carries the weight of that loss each and every day.

05/22/2026

From beignets to breakthroughs, New Orleans does everything big! We will be at ADA 2026 Scientific Sessions, Booth 2220, showcasing DiabetesNow, our comprehensive 16-gene panel for identifying monogenic diabetes alongside pan-ancestry polygenic risk scores and GenProb-T1D. See us and discover how DiabetesNow, backed by dedicated genetic counseling, can bring clarity to even the most complex diabetes cases.

Learn More: https://geneticsnow.com/diabetesnow

05/19/2026

From the exhibit floor to the nation's capital, AUA 2026 was a moment we will not forget! 🔬

Our team loved connecting with so many brilliant minds and walking attendees through our latest innovations. Did you miss us? Visit our website to explore everything we have to offer!

https://www.gopathdx.com

05/15/2026

From the monuments to the microscope — AUA is officially here! 🏛️

Find us at booth 3515 to explore our ProstateNow germline panel and Triplet Approach to Managing Cancer. This integrative strategy uses hereditary germline panels, comprehensive genomic profiling, and MRD testing to support personalized cancer care from every angle.

05/11/2026

GoPath Diagnostics is proud to announce an exclusive U.S. partnership with OncoAssure Ltd. to bring OncoAssure Prostate to clinicians across the country.

Designed for men diagnosed with localized prostate cancer, OncoAssure Prostate combines genomic and clinical data to help better stratify risk and support more informed treatment decisions.

Clinical validation demonstrated that patients with higher-risk scores were:
• 4.4× more likely to experience biochemical recurrence within 5 years
• 9.7× more likely to have adverse pathology findings

As prostate cancer management continues moving toward more personalized care, tools that help distinguish indolent from aggressive disease are becoming increasingly important in treatment planning.

Visit us at AUA 2026 in Washington, D.C., at Booth 3515 to learn more about the partnership and how OncoAssure Prostate may help support clinical decision-making.

Read the full press release: https://www.gopathdx.com/news/tpost/k8bmlm2l31-oncoassure-and-gopath-diagnostics-announ

05/08/2026

Today, we join the global community in recognizing World Ovarian Cancer Day. Ovarian cancer remains one of the most challenging gynecologic cancers to detect early, making awareness and continued research critical. We are proud to stand alongside patients, caregivers, and advocates working toward better outcomes for women everywhere.

Learn more from the World Ovarian Cancer Coalition: https://worldovariancancercoalition.org/world-ovarian-cancer-day/